Alex Galbraith - September 4, 2024 We perform significantly better than the EPO average at oppositions We really are experts when it comes to opposing patents and our enviable success rate speaks for ...
Alex Galbraith - November 17, 2023 The first CRISPR treatment – Casgevy wins UK approval for sickle cell disease In a world first, the UK medicines regulator has given the green light to a therapy employing ...
Alex Galbraith - September 1, 2023 Gene therapy – the status quo and future trends The uptick in recent approvals in the gene therapy space is emblematic of a field which is now ...
Rebecca Tollervey - May 9, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal: Part 2 – inventive step We have conducted a review of Board of Appeal decisions relating to antibody patents published ...
Rebecca Tollervey - February 1, 2023 Patenting antibodies – the latest developments from the EPO Boards of Appeal The prosecution of patent applications relating to antibodies involves particular considerations. ...
Alex Galbraith - December 1, 2022 Antibody therapy for pets – following the human lead Over recent decades monoclonal antibody (mAb) therapy has developed from a standing start to become ...
Matthew Naylor - September 23, 2022 UPC: Rules of Procedure finalised and in force The Unitary Patent Court now has a revised set of Rules of Procedure. These came into force on 1 ...
Joseph Morgan - October 14, 2021 CRISPR - the future of gene editing In this Forward: On Demand vlog, Joseph Morgan and Alex Galbraith explore what CRISPR/Cas9 is, how ...
Alex Galbraith - May 12, 2021 Diagnosing concussion: liquid biopsy is changing the game Rugby, along with many other contact sports such as football, boxing and American football, has ...
Alex Galbraith - March 8, 2021 Detecting progress: liquid biopsy in lung cancer Lung cancer remained the leading cause of cancer death in 2020 with an estimated 1.8 million deaths ...